Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: Results of an Argentinean multicentre phase II trial

British Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 846-849

  Van Kooten, M ^a   Traine, G ^b   Cinat, G ^c   Cazap, E ^d   Zori Comba, A ^f   Vicente, H ^g   Sena, S ^e   Rodriguez Nievas, O ^h   Orlando, M ^a  

^a INSTITUTO ALEXANDER FLEMING   (Argentina)

^b Hospital Israelita   (Argentina)

^c Oncology Department   (Argentina)

^d Instituto Estevez   (Argentina)

^e HOSPITAL ALEMÁN   (Argentina)

^f Hospital General de Agudos Dr Abel Zubizarreta   (Argentina)

^g Tornu Hospital   (Argentina)

^h Centro Oncologico de Excetencia   (Argentina)

Author keywords

Advanced non small cell lung cancer; Gemcitabine; Second line chemotherapy

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; GEMCITABINE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARGENTINA; ARTICLE; ASTHENIA; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DYSPNEA; EDEMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RASH; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 0032748061     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690774     Document Type: Article

References (19)

1. Abratt RP, Bezwoda WR, Falkson G, et al (1994) Efficacy and safety profile of gemcitabine in non small cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540
2. Abratt RP, Bezwoda WR, Goedhale L, et al (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15: 744-749
3. Anderson H, Lund B, Bach E, et al (1994) Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826
4. Crino L, Mosconi A, Scagliotti G, et al (1997a) Salvage therapy in pretreated, advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 17: 1603 (Abstract)
5. Crino L, Scagliotti G, Marangolo M, et al (1997b) Cisplatin-gemcitabine combination in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol: 15: 297-303
6. Einhorn L (1997) Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer. Hoosier Oncology Group Study. Semin Oncol 24: S8 24-S8 26
7. Fossella F, Lee JS and Hong WK (1997) Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24: 455-462
8. Gatzemier U, Shepherd, FA, Le-Chevalier T, et al (1996) Activity of gemcitabine in patients with non small cell lung cancer: a multicenter extended phase II study. Eur J Cancer 32: 243-248
9. Guerra J, Lianes P, Paz-Ares L, et al (1997) Efficacy and toxicity profile of gemcitabine in previously treated patients with non-small cell lung cancer. Lung Cancer (suppl) World Conference on Lung Cancer, Dublin (abstract no. 99).
10. Hertel LW, Boder GB, Kroin, JS, et al (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422
11. Ihde DC (1992) Chemotherapy of lung cancer. N Engl J Med 327: 1434-1441
12. Lund B, Kristjansen PEG, Hansen HH (1993) Clinical and preclinical activity of 2′,2′-difluro-2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19: 45-55
13. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909
14. Piazza E, Isa L, Pavia GF, et al (1997) Gemcitabine in the treatment of pretreated metastatic non-small cell lung cancer: a preliminary report. Lung Cancer (suppl) World Conference on Lung Cancer, Dublin (Abstract no 138).
15. Rapp E, Parer IL, Willan A, et al (1988) Chemotherapy can prolong survival in patents with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633-641
16. Rosvold E, Langer CJ, Schelder R, et al (1998) Salvage therapy with gemcitabine in advanced non-small cell lung cancer progressing after prior carboplatin-paclitaxel. Proc Am Soc Clin Oncol 12: 1797
17. Rothenberg ML, Moore MJ, Cripps MC, et al (1996) A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 7: 347-352
18. Shepherd F, Cormier Y, Burkes R, et al (1997) Phase II trial study of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24 (suppl 8): S27-S30
19. Word Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment, p. 48. WHO: Geneva